文献速递腹部技术与安全CT

新辅助化疗后最大淋巴结的缓解程度可预测局部进展期胃癌的长期预后

The largest lymph node defined response to neoadjuvant chemotherapy can predict long-term prognosis in locally advanced gastric cancer.
PubMed 文献 · Abdom Radiol (NY) · 2023-09-27

该研究回顾性分析41例接受新辅助化疗后根治性手术的局部进展期胃癌患者,测量化疗前后CT上最大淋巴结和原发肿瘤的缩小百分比。淋巴结缓解者中位总生存期显著长于未缓解者(20.6 vs 16.6个月,p=0.031),而原发肿瘤缓解组间无显著差异(p=0.377)。多因素分析显示淋巴结缩小和淋巴结缓解是总生存期的独立预测因素。

要点

  • 新辅助化疗后最大淋巴结缩小百分比可反映肿瘤缓解,并预测长期总生存期。
  • 淋巴结缓解者中位总生存期20.6个月,未缓解者16.6个月,差异有统计学意义(p=0.031)。
  • 原发肿瘤缓解与总生存期无显著相关(p=0.377),评估时应重点关注淋巴结变化。

核心结论

  • 新辅助化疗期间最大淋巴结的变化可反映肿瘤对化疗的缓解,淋巴结定义的缓解有助于预测接受新辅助化疗后根治性手术的局部进展期胃癌患者的长期总生存期。

研究设计与样本

  • 回顾性分析一项前瞻性临床试验中接受新辅助化疗后根治性手术的局部进展期胃癌患者41例,测量初始至新辅助化疗后CT上最大淋巴结和原发肿瘤的缩小百分比。

关键影像表现/征象

  • 新辅助化疗后最大淋巴结缩小百分比用于定义淋巴结缓解,原发肿瘤缩小百分比用于定义原发肿瘤缓解。
  • 淋巴结缓解者中位总生存期20.6个月,淋巴结未缓解者16.6个月(p=0.031)。
  • 原发肿瘤缓解者中位总生存期18.5个月,原发肿瘤未缓解者19.0个月(p=0.377)。

诊断标准与关键数值

  • 41例患者中28例(68.3%)定义为淋巴结缓解者,17例(41.5%)定义为原发肿瘤缓解者。
  • 多因素分析中阳性淋巴结数目(p=0.004,HR=1.284)、复发(p=0.024,HR=3556)、淋巴结缩小(p=0.022,HR=0.930)和淋巴结缓解(p=0.033,HR=0.008)与总生存期独立相关。

临床应用与阅片要点

  • 在新辅助化疗后CT评估中,测量最大淋巴结的缩小百分比有助于判断肿瘤缓解和预测长期总生存期,原发肿瘤缩小与总生存期的关联在本队列中无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: The assessment of tumor response to neoadjuvant chemotherapy (NACT) in locally advanced gastric cancer (LAGC) remain challenging. We aimed to explore the potential role of peri-NACT change of the largest lymph node (LN) and primary tumor (P-T) in the prediction of tumor response and patient overall survival (OS) in LAGC.

METHODS: A cohort of LAGC patients who underwent NACT followed by radical surgery from a prospective clinical trial were retrospectively analyzed. The percentage change of the largest LN and P-T from initial to post-NACT Computed Tomography (CT) were measured. Tumor response was defined by the change of LN (LN-response) and P-T (P-T-response), respectively. A multivariate Cox model was constructed to examine if P-T- and LN-determined response had significant predictive ability for OS when adjusting with other possible prognostic factors.

RESULTS: Of the 41 patients, 28 (68.3%) was defined as LN-responders to NACT, and 17 (41.5%) patients was defined as P-T-responders. When the cohort was stratified by LN response standard, LN-responders showed a significant longer median OS than LN-nonresponders (p = 0.031, 20.6 vs 16.6 months). When stratified by primary tumor response, no significant difference in OS was observed between P-T-responders and P-T-nonresponders (p = 0.377, 18.5 vs 19.0 months). In the multivariate analysis, number of positive LN (p = 0.004, hazard ratio [HR] = 1.284), recurrence (p = 0.024, HR =3556), LN shrinkage (p = 0.022, HR = 0.930) and LN-response (p = 0.033, HR = 0.008) were observed with independent association with OS.

CONCLUSIONS: Peri-NACT change of the largest LN could reflect tumor response to NACT, and LN-defined response was useful in predicting the long-term prognosis (OS) of LAGC patients who underwent NACT followed by radical surgery.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Liu L, Wang Y, Liu T, et al. The largest lymph node defined response to neoadjuvant chemotherapy can predict long-term prognosis in locally advanced gastric cancer. Abdom Radiol (NY). 2023. PMID: 37755476. doi:10.1007/s00261-023-04048-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。